Abstract
Paclitaxel is an antineoplastic agent derived from the bark of the western yew, Taxus brevifolia, with a broad spectrum of activity. Because paclitaxel promotes microtubule assembly, neurotoxicity is one of its side effects. Clinical use of paclitaxel has led to peripheral neuropathy and this has been demonstrated to be dependent upon the dose administered, the duration of the infusion, and the schedule of administration. Vehicles in the drug formulation, for example Cremophor in Taxol®, have been investigated for their potential to induce peripheral neuropathy. A variety of neuroprotective agents have been tested in animal and clinical studies to prevent paclitaxel neurotoxicity. Recently, novel paclitaxel formulations have been developed to minimize toxicities. This review focuses on recent advances in the etiology of paclitaxel-mediated peripheral neurotoxicity, and discusses current and ongoing strategies for amelioration of this side effect.
Keywords: Taxol, cremophor, ABI-007, peripheral neuropathy
Current Neuropharmacology
Title: Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Volume: 4 Issue: 2
Author(s): Charity D. Scripture, William D. Figg and Alex Sparreboom
Affiliation:
Keywords: Taxol, cremophor, ABI-007, peripheral neuropathy
Abstract: Paclitaxel is an antineoplastic agent derived from the bark of the western yew, Taxus brevifolia, with a broad spectrum of activity. Because paclitaxel promotes microtubule assembly, neurotoxicity is one of its side effects. Clinical use of paclitaxel has led to peripheral neuropathy and this has been demonstrated to be dependent upon the dose administered, the duration of the infusion, and the schedule of administration. Vehicles in the drug formulation, for example Cremophor in Taxol®, have been investigated for their potential to induce peripheral neuropathy. A variety of neuroprotective agents have been tested in animal and clinical studies to prevent paclitaxel neurotoxicity. Recently, novel paclitaxel formulations have been developed to minimize toxicities. This review focuses on recent advances in the etiology of paclitaxel-mediated peripheral neurotoxicity, and discusses current and ongoing strategies for amelioration of this side effect.
Export Options
About this article
Cite this article as:
Scripture D. Charity, Figg D. William and Sparreboom Alex, Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives, Current Neuropharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157015906776359568
DOI https://dx.doi.org/10.2174/157015906776359568 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Current Medicinal Chemistry Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder: A Systematic Review
Current Neuropharmacology Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Therapeutic and Mechanistic Effects of Curcumin in Huntington’s Disease
Current Neuropharmacology Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design Antiglucocorticoids, Neurogenesis and Depression
Mini-Reviews in Medicinal Chemistry Alpha-Secretase As a Therapeutic Target
Current Alzheimer Research Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Frontotemporal Dementia Caused by CHMP2B Mutations
Current Alzheimer Research Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology Neuro-endocrine Markers in Neoplasms. Diagnostic Interest and Future Prospects
Current Proteomics Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents <sup>11</sup>C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications
Current Radiopharmaceuticals Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Functionalized Mesoporous Silica Nanoparticles: A Possible Strategy to Target Cancer Cells Reducing Peripheral Nervous System Uptake
Current Medicinal Chemistry Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Amyloid Precursor Protein Processing in Vivo - Insights from a Chemically- Induced Constitutive Overactivation of Protein Kinase C in Guinea Pig Brain
Current Medicinal Chemistry Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy